Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering

A meta-analysis tackled the question of whether baseline LDL-C level influences the extent to which mortality-based outcomes are achieved following LDL-C lowering therapy.

A meta-analysis tackled the question of whether baseline LDL-C level influences the extent to which mortality-based outcomes are achieved following LDL-C lowering therapy. Researchers considered 34 studies with more than 270,000 participants, 136,299 of whom received more intensive pharmacological intervention for high cholesterol and 133,989 of whom received less intensive intervention, such as randomization to a placebo or control group. More intensive exposure was associated with a deeper reduction in risk of both all-cause and cardiovascular mortality: the primary co-outcomes. This correlation was absent, however, among patients whose baseline LDL-C level was below 100 mg/dL. The findings suggest that the greatest benefit from LDL-C–lowering therapy may occur among patients with baseline LDL-C levels at or above that threshold.